household population
IGF-1 LR3s modified structure reduces its binding to IGF binding proteins (IGFBPs), which normally sequester 99% of circulating IGF-1 and limit bioavailability
Obesity changes your muscle 'engine type': Excess weight shifts muscle fiber composition, reducing efficient, fat-burning Type I fibers and increasing less efficient, fatigue-prone Type IIx fibers, worsening metabolic flexibility
Temporary telogen effluvium may occur secondary to rapid weight loss, caloric restriction, or significant metabolic changes similar observations have been reported with other obesity therapies and are typically reversible
High Potency Creatine MonohydrateEach serving delivers 5000 mg of creatine monohydrate, supporting increased muscle performance and strength
This 18-month window provides a significant opportunity for patients to address obesity-related health risks using advanced pharmacological tools previously unavailable under Medicare